Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Persistent Corneal Epithelial Defect
- Main trialPhase 2
- “Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess corneal healing and safety.”In the company’s words, NCT07886268 on ClinicalTrials.gov
Other drugs for Persistent Corneal Epithelial Defect
- CenegerminDompé Farmaceutici S.p.A · Phase 3
- FreneslerbartRegeneron · Phase 3
- MevonlerbartRegeneron · Phase 3
- REGN1908-1909Regeneron · Phase 3
- T1695Laboratoires Thea · Phase 2
- TL-925Telios Pharma, Inc. · Phase 2
Coming up1
- 7 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 7 Jul 2028 | A Study to Evaluate the Efficacy and Safety of TP-06 for PCED |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026